WO2005110413A3 - Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions - Google Patents

Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions Download PDF

Info

Publication number
WO2005110413A3
WO2005110413A3 PCT/EP2005/052281 EP2005052281W WO2005110413A3 WO 2005110413 A3 WO2005110413 A3 WO 2005110413A3 EP 2005052281 W EP2005052281 W EP 2005052281W WO 2005110413 A3 WO2005110413 A3 WO 2005110413A3
Authority
WO
WIPO (PCT)
Prior art keywords
arylpiperazines
sulfamoyl
prophylaxis
obesity
treatment
Prior art date
Application number
PCT/EP2005/052281
Other languages
French (fr)
Other versions
WO2005110413A2 (en
Inventor
Jochen Antel
Peter-Colin Gregory
Uwe Reinecker
Michael Wurl
Uwe Schoen
Harald Waldeck
Michael Firnges
Dania Reiche
Original Assignee
Solvay Pharm Gmbh
Jochen Antel
Peter-Colin Gregory
Uwe Reinecker
Michael Wurl
Uwe Schoen
Harald Waldeck
Michael Firnges
Dania Reiche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh, Jochen Antel, Peter-Colin Gregory, Uwe Reinecker, Michael Wurl, Uwe Schoen, Harald Waldeck, Michael Firnges, Dania Reiche filed Critical Solvay Pharm Gmbh
Priority to BRPI0510137-9A priority Critical patent/BRPI0510137A/en
Priority to MXPA06013299A priority patent/MXPA06013299A/en
Priority to CA002567166A priority patent/CA2567166A1/en
Priority to AU2005244450A priority patent/AU2005244450B2/en
Priority to JP2007517257A priority patent/JP2007538054A/en
Priority to EP05749492A priority patent/EP1750712A2/en
Priority to CN2005800159695A priority patent/CN1997370B/en
Publication of WO2005110413A2 publication Critical patent/WO2005110413A2/en
Publication of WO2005110413A3 publication Critical patent/WO2005110413A3/en
Priority to IL178903A priority patent/IL178903A0/en
Priority to NO20065835A priority patent/NO20065835L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Abstract

The present invention relates to the use of known and novel N-sulfamoyl-N'­arylpiperazines and their physiologically compatible acid addition salts for the prophylaxis or treatment of obesity and related conditions.
PCT/EP2005/052281 2004-05-19 2005-05-18 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions WO2005110413A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0510137-9A BRPI0510137A (en) 2004-05-19 2005-05-18 n-sulfamoyl-n'-arylpiperazine containing medicines for the prophylaxis or treatment of obesity and related conditions
MXPA06013299A MXPA06013299A (en) 2004-05-19 2005-05-18 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions.
CA002567166A CA2567166A1 (en) 2004-05-19 2005-05-18 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
AU2005244450A AU2005244450B2 (en) 2004-05-19 2005-05-18 Medicaments containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
JP2007517257A JP2007538054A (en) 2004-05-19 2005-05-18 Drug containing N-sulfamoyl-N'-arylpiperazine for the prevention or treatment of obesity and related diseases
EP05749492A EP1750712A2 (en) 2004-05-19 2005-05-18 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
CN2005800159695A CN1997370B (en) 2004-05-19 2005-05-18 Use of n-sulfamoyl-n'-arylpiperazines in preparing medicine for the prophylaxis or treatment of obesity and related conditions
IL178903A IL178903A0 (en) 2004-05-19 2006-10-26 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
NO20065835A NO20065835L (en) 2004-05-19 2006-12-18 Medicines containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57223604P 2004-05-19 2004-05-19
US60/572,236 2004-05-19
EP04102210 2004-05-19
EP04102210.4 2004-05-19

Publications (2)

Publication Number Publication Date
WO2005110413A2 WO2005110413A2 (en) 2005-11-24
WO2005110413A3 true WO2005110413A3 (en) 2006-07-13

Family

ID=34969508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/052281 WO2005110413A2 (en) 2004-05-19 2005-05-18 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Country Status (11)

Country Link
EP (1) EP1750712A2 (en)
JP (1) JP2007538054A (en)
CN (1) CN1997370B (en)
AU (1) AU2005244450B2 (en)
BR (1) BRPI0510137A (en)
CA (1) CA2567166A1 (en)
IL (1) IL178903A0 (en)
MX (1) MXPA06013299A (en)
NO (1) NO20065835L (en)
RU (1) RU2395503C2 (en)
WO (1) WO2005110413A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
DE602007008831D1 (en) * 2006-01-23 2010-10-14 Hoffmann La Roche CYCLOHEXYL-SULFONAMIDE DERIVATIVES WITH H3 RECEPTOR ACTIVITY
NZ579229A (en) 2007-01-25 2011-07-29 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
PE20120811A1 (en) * 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc CCR3 ARYLSULFONAMIDE ANTAGONISTS
RU2445963C2 (en) * 2010-07-09 2012-03-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical antidiabetic composition
LT2968316T (en) 2013-03-13 2019-10-25 Forma Therapeutics Inc 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
CN113382633A (en) 2018-10-29 2021-09-10 福马治疗股份有限公司 Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748125A (en) * 1954-04-26 1956-05-29 American Cyanamid Co 1-substituted-4-sulfamylpiperazine and method of preparing the same
US3709677A (en) * 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
WO1995009151A1 (en) * 1993-09-28 1995-04-06 Ciba-Geigy Ag Acylated sulphonamides as insecticides and acaricides
EP0958287B1 (en) * 1997-01-23 2002-09-11 F. Hoffmann-La Roche Ag Sulfamide-metalloprotease inhibitors
WO2003075929A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
WO2003103661A1 (en) * 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
WO2005005382A2 (en) * 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2030116A1 (en) 1969-01-02 1970-10-30 Sandoz Sa Herbicide compositions and prepn
DE4025387A1 (en) 1990-08-10 1992-02-13 Hoechst Ag SUBSTITUTED PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS REAGENTS
DE10035227A1 (en) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity
EP2311827A1 (en) 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748125A (en) * 1954-04-26 1956-05-29 American Cyanamid Co 1-substituted-4-sulfamylpiperazine and method of preparing the same
US3709677A (en) * 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
WO1995009151A1 (en) * 1993-09-28 1995-04-06 Ciba-Geigy Ag Acylated sulphonamides as insecticides and acaricides
EP0958287B1 (en) * 1997-01-23 2002-09-11 F. Hoffmann-La Roche Ag Sulfamide-metalloprotease inhibitors
WO2003075929A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
WO2003103661A1 (en) * 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
WO2005005382A2 (en) * 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"MARTINDALE, The complete drug reference", 2003, PHARMACEUTICAL PRESS, XP002372618 *

Also Published As

Publication number Publication date
AU2005244450B2 (en) 2010-08-19
IL178903A0 (en) 2007-03-08
JP2007538054A (en) 2007-12-27
WO2005110413A2 (en) 2005-11-24
BRPI0510137A (en) 2007-10-02
MXPA06013299A (en) 2007-02-02
AU2005244450A1 (en) 2005-11-24
RU2006144812A (en) 2008-06-27
CA2567166A1 (en) 2005-11-24
RU2395503C2 (en) 2010-07-27
NO20065835L (en) 2007-02-16
CN1997370A (en) 2007-07-11
CN1997370B (en) 2011-06-01
EP1750712A2 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
GEP20125565B (en) Lactam compounds and their pharmaceutical use
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
WO2009051718A3 (en) Calcium receptor modulating agents
WO2006023843A3 (en) Novel heterocycles
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
TW200728281A (en) Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
TW200602057A (en) Medicaments containing n-sulfamoyl-n' -arylpiperazines for the prophylaxis or treatment of obesity and related conditions
WO2004055001A3 (en) Rabeprazole calcium
WO2009077485A3 (en) 1(2)h-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
WO2007093608A8 (en) Drug combinations for the treatment of respiratory tract diseases
ATE427108T1 (en) MEDICINAL PRODUCTS CONTAINING ANTICHOLINERGICS FOR THE TREATMENT OF DISEASES OF THE URINARY TRACT

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 178903

Country of ref document: IL

Ref document number: 200608918

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005749492

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12006502246

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013299

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2567166

Country of ref document: CA

Ref document number: 2005244450

Country of ref document: AU

Ref document number: 2007517257

Country of ref document: JP

Ref document number: 200580015969.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: DZP2005000559

Country of ref document: DZ

Ref document number: DZP2006000559

Country of ref document: DZ

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 7543/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005244450

Country of ref document: AU

Date of ref document: 20050518

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020067026386

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005244450

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006144812

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005749492

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067026386

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0510137

Country of ref document: BR